Seeing Is Believing
NBRV is currently covered by 1 analysts with an average price target of $-22. This is a potential upside of $-22.4 (-5600%) from yesterday's end of day stock price of $0.4.
Nabriva Therapeutics AG's activity chart (see below) currently has 0 price targets and 7 ratings on display. The stock rating distribution of NBRV is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 75% with an average time for these price targets to be met of 145.5 days.
Highest price target for NBRV is $7, Lowest price target is $1, average price target is $-22.
Most recent stock forecast was given by CARL BYRNES from NORTHLAND CAPITAL MARKETS on 06-Jan-2023. First documented stock forecast 07-Dec-2020.
Currently out of the existing stock ratings of NBRV, 2 are a BUY (100%).
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
1
$0.6 (150.00%)
18
1 years 2 months 22 days ago
1/2 (50%)
$-0.3 (-23.08%)
207
Hold
50
$49.6 (12400.00%)
3 years 3 months 21 days ago
1/1 (100%)
$-44.5 (-47.09%)
84
What is NBRV (Nabriva Therapeutics AG) average time for price targets to be met?
Which analyst has the current highest performing score on NBRV (Nabriva Therapeutics AG) with a proven track record?
Which analyst has the current lower performing score on NBRV (Nabriva Therapeutics AG) with a proven track record?
Which analyst has the most public recommendations on NBRV (Nabriva Therapeutics AG)?
Which analyst is the currently most bullish on NBRV (Nabriva Therapeutics AG)?
Which analyst is the currently most reserved on NBRV (Nabriva Therapeutics AG)?